Development of a safe and effective vaccine for induction of mucosal immunity to the human immunodeficiency virus (HIV) envelope glycoprotein (Env, gp160) represents the best hope for containing the spread of an HIV epidemic worldwide. The highly attenuated modified vaccinia virus Ankara (MVA) is a laboratory virus well suited as a safe vaccine vector. However, the presence of pre-existing immunity to Vaccinia virus in the adult population represents a hindrance that limits the application of the MVA vector for inducing immunity to HIV antigens. Here, cationic liposomes were covalently attached to the surface of recombinant MVA expressing the HIV-1 strain IIIB Env glycoprotein and β-galactosidase (MVAIIIB/β-gal) using tresylmonomethoxypolyethylene glycol (TMPEG) grafted into a lipid membrane without compromising viral infectivity in vitro and in vivo. The orally administered MVAIIIB/β-gal–TMPEG/liposome complexes were capable of delivering the transgenes to mucosal tissues in mice with pre-existing poxvirus immunity based on β-galactosidase gene expression in intestinal tissues measured 18 h after infection. Importantly, the MVAIIIB/β-gal–TMPEG/liposome complexes enhanced Env-specific cellular and humoral immune responses in the mucosal and systemic tissues after repeated oral immunization of BALB/c mice. This approach may prove useful for induction of protective immunity against infectious diseases and cancer in populations with pre-existing immunity to vaccinia from smallpox vaccination.
AbaciogluY. H.,
FoutsT. R.,
LamanJ. D.,
ClaassenE.,
PincusS. H.,
MooreJ. P.,
RobyC. A.,
Kamin-LewisR.,
LewisG. K.1994; Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 10:371–381[CrossRef]
BelyakovI. M.,
WyattL. S.,
AhlersJ. D.,
EarlP.,
PendletonC. D.,
KelsallB. L.,
StroberW.,
MossB.,
BerzofskyJ. A.1998; Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 72:8264–8272
BelyakovI. M.,
MossB.,
StroberW.,
BerzofskyJ. A.1999; Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A 96:4512–4517[CrossRef]
BelyakovI. M.,
EarlP.,
DzutsevA.,
KuznetsovV. A.,
LemonM.,
WyattL. S.,
SnyderJ. T.,
AhlersJ. D.,
FranchiniG.other authors2003; Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 100:9458–9463[CrossRef]
BelyakovI. M.,
HammondS. A.,
AhlersJ. D.,
GlennG. M.,
BerzofskyJ. A.2004; Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113:998–1007[CrossRef]
BenderB. S.,
RoweC. A.,
TaylorS. F.,
WyattL. S.,
MossB.,
SmallP. A., Jr.
1996; Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 70:6418–6424
CooneyE. L.,
CollierA. C.,
GreenbergP. D.,
CoombsR. W.,
ZarlingJ.,
ArdittiD. E.,
HoffmanM. C.,
HuS.-L.,
CoreyL.1991; Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567–572[CrossRef]
DelgadoC.,
PatelJ. N.,
FrancisG. E.,
FisherD.1990; Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem 12:119–128
FrancisG. E.,
FisherD.,
DelgadoC.,
MalikF.,
GardinerA.,
NealeD.1998; PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 68:1–18[CrossRef]
FullerD. H.,
RajakumarP. A.,
WilsonL. A.,
TrichelA. M.,
FullerJ. T.,
ShipleyT.,
WuM. S.,
WeisK.,
RinaldoC. R.other authors2002; Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 76:3309–3317[CrossRef]
GherardiM. M.,
EstebanM.1999; Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17:1074–1083[CrossRef]
GregoriadisG.,
RymanB. E.1972; Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases. Eur J Biochem 24:485–491[CrossRef]
HankeT.,
BlanchardT. J.,
SchneiderJ.,
HannanC. M.,
BeckerM.,
GilbertS. C.,
HillA. V. S.,
SmithG. L.,
McMichaelA.1998; Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439–445[CrossRef]
HarasymT. O.,
TardiP.,
LongmanS. A.,
AnsellS. M.,
BallyM. B.,
CullisP. R.,
ChoiL. S. L.1995; Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6:187–194[CrossRef]
IshiiN.,
FukushimaJ.,
KanekoT.,
OkadaE.,
TaniK.,
TanakaS. I.,
HamajimaK.,
XinK.-Q.,
KawamotoS.other authors1997; Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 13:1421–1428[CrossRef]
JonesD. H.,
CorrisS.,
McDonaldS.,
CleggJ. C. S.,
FarrarG. H.1997; Poly(dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 15:814–817[CrossRef]
KiszkaI.,
KmieciakD.,
GzylJ.,
NaitoT.,
BolestaE.,
SieronA.,
SinghS. P.,
SrinivasanA.,
TrinchieriG.other authors2002; Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates. J Virol 76:4222–4232[CrossRef]
KonishiE.,
KuraneI.,
MasonP. W.,
ShopeR. E.,
EnnisF. A.1997; Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice. Virology 227:353–360[CrossRef]
KresinaT. F.,
MathiesonB.1999; Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis and extramural research programs at the National Institutes of Health. J Infect Dis 179 (Suppl. 3):S392–S396[CrossRef]
MayrA.,
SticklH.,
MullerH. K.,
DannerK.,
SingerH.1978; The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zentralbl Bakteriol 167:375–390 (in German
McGheeJ. R.,
MesteckyJ.1990; In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin North Am 4:315–341
MesteckyJ.,
EldridgeJ. H.1991; Targeting and controlled release of antigens for the effective induction of secretory antibody responses. Curr Opin Immunol 3:492–495[CrossRef]
MeyerH.,
SutterG.,
MayrA.1991; Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72:1031–1038[CrossRef]
O'RiordanC. R.,
LachapelleA.,
DelgadoC.,
ParkesV.,
WadsworthS. C.,
SmithA. E.,
FrancisG. E.1999; PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10:1349–1358[CrossRef]
SchneiderJ.,
GilbertS. C.,
BlanchardT. J.,
HankeT.,
RobsonK. J.,
HannanC. M.,
BeckerM.,
SindenR.,
SmithG. L.,
HillA. V.1998; Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4:397–402[CrossRef]
SeniorJ.,
DelgadoC.,
FisherD.,
TilcockC.,
GregoriadisG.1991; Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062:77–82[CrossRef]
SnyderJ. T.,
BelyakovI. M.,
DzutsevA.,
LemonnierF.,
BerzofskyJ. A.2004; Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 78:7052–7060[CrossRef]
SutterG.,
MossB.1995; Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 84:195–200
TakahashiH.,
NakagawaY.,
LeggattG. R.,
IshidaY.,
SaitoT.,
YokomuroK.,
BerzofskyJ. A.1996; Inactivation of human immunodeficiency virus (HIV)-1 envelope-specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism?. J Exp Med 183:879–889[CrossRef]
TartagliaJ.,
PerkusM. E.,
TaylorJ.,
NortonE. K.,
AudonnetJ.-C.,
CoxW. I.,
DavisS. W.,
van der HoevenJ.,
MeignierB.other authors1992; NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232[CrossRef]
WyattL. S.,
ShorsS. T.,
MurphyB. R.,
MossB.1996; Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451–1458[CrossRef]
ZalipskyS.1993; Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjug Chem 4:296–299[CrossRef]